At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 54 enrolled
Drug / intervention
somatropindrug
Likely dose
somatropin 0.469 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea
In Brief
A Phase 3 clinical trial evaluating somatropin for Growth Disorder and Idiopathic Short Stature. Completed, enrolled 54 participants across 8 sites.
Detailed Summary
This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of recombinant human growth hormone (hGH) in subjects with idiopathic short stature in Korea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGrowth Disorder, Idiopathic Short Stature
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedJan 29, 2013
Enrollment StartJan 17, 2013
Primary CompletionDec 17, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.4 years ago
Interventions
somatropindrug
A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.